Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioTime, Inc.

Market Cap 299M 258M 237M 223M 419M 28.28B 423M 2.81B 1.09B 13.85B 1.12B 1.1B 48B P/E Ratio 2026 *
-17.1x
P/E Ratio 2027 * -13.1x
Enterprise Value 299M 258M 237M 223M 419M 28.28B 423M 2.81B 1.09B 13.85B 1.12B 1.1B 48B EV / Sales 2026 *
16.7x
EV / Sales 2027 * 16.5x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Operating Officer - 2010-11-30
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+7.37%-11.55% - - 307M
-0.12%-0.18%-12.80%-12.90% 43.58B
-2.17%+4.70%+293.71%+535.99% 34.03B
+0.44%-3.80%+12.51%-17.06% 29.77B
-1.60%-1.58%-0.19%+31.82% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+3.54%+8.43% - - 13.87B
-1.26%-1.11%+53.37%+108.10% 13.35B
-1.04%-3.48%+2.42%+1.98% 12.85B
-1.18%-2.00%+107.41%+78.18% 12.22B
Average +0.37%+1.10%+58.80%+93.51% 23.88B
Weighted average by Cap. -0.53%+0.87%+60.75%+104.95%

Financials

2026 *2027 *
Net sales 17.94M 15.46M 14.23M 13.36M 25.09M 1.7B 25.36M 168M 65.53M 830M 67.32M 65.89M 2.88B 18.09M 15.59M 14.36M 13.48M 25.31M 1.71B 25.58M 170M 66.1M 838M 67.9M 66.46M 2.9B
Net income -23.79M -20.5M -18.88M -17.72M -33.28M -2.25B -33.63M -223M -86.9M -1.1B -89.27M -87.38M -3.82B -31.66M -27.28M -25.12M -23.59M -44.29M -2.99B -44.76M -297M -116M -1.47B -119M -116M -5.08B
Net Debt - -
Logo BioTime, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!